Accessibility Menu
Cytek Biosciences logo

Cytek Biosciences(NASDAQ) CTKB

Current Price$4.53
Market Cap$586.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-76%
5 Year-76%
1 Year+40%
1 Month+18%
Cytek Biosciences last closing stock price
MetricPriceDate
Last closeUSD 4.542026-07-22
Cytek Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.37%USD 4.652026-07-15
1 month+17.62%USD 3.862026-06-22
3 month+6.57%USD 4.262026-04-23
Year to date-10.1%USD 5.052025-12-31
1 year+39.69%USD 3.252025-07-22
3 year-48.99%USD 8.902023-07-21
5 year-75.8%USD 18.762021-07-23
Since inception-75.8%USD 18.762021-07-23

Cytek Biosciences Financials at a Glance

Market Cap

$586.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$204.17M

Net Income (TTM)

-$74.00M

EPS (TTM)

-$0.58

P/E Ratio

-7.86

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$4.53

Volume

0

Open

$4.59

Previous Close

$4.53

Daily Range

$4.49 - $4.59

52-Week Range

$3.20 - $6.18

Estimated Earnings Date

Aug 5, 2026

CTKB News

scientists high five smile

Why Shares of Cytek Biosciences Dropped This Week

James HalleyMay 12, 2023

CTKB: Motley Fool Moneyball Superscore

51

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cytek Biosciences

Cytek Biosciences offers cell analysis tools for research and clinical use. Its products assist pharmaceutical and biopharma companies in identifying cell types. Cytek's technology advances biomedical research.

Products and Services

Spectrum Flow Cytometers: Aurora and Northern Lights systems for detailed cell analysis.

Cell Sorter System: Aurora cell sorter for diverse cell analysis applications.

Reagents and Kits: cFluor reagents and 25-color assay for immune cell profiling.

Automated Systems: Micro-sampling and sample loader systems for seamless integration.

Software: SpectroFlo for data analysis and quality control.

Customer Support: Comprehensive tools and services for client assistance.

Growth and Expansion

Expanded global presence in North America, Europe, China, and Asia-Pacific.

Increased product offerings with advanced cell analysis technologies.

Strengthened distribution through direct sales and partnerships.

What Makes Cytek Special

Cytek's full spectrum profiling technology sets it apart in cell analysis. Its global distribution network enhances market reach and customer access.

Five Things You Need to Know

Revenue for nine months ended September 30, 2024, was $142.98 million.

Product revenue reached $108.24 million by September 30, 2024.

Gross profit for the same period was $77.45 million.

Operating loss decreased to $23.51 million in 2024.

Net loss for the nine months ended September 30, 2024, was $15.66 million.

Bottom Line

Cytek Biosciences continues to innovate in cell analysis, expanding its global footprint. Its technology supports critical advancements in biomedical research.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

700

CEO

Wen Bin Jiang, PhD

Website

cytekbio.com

Headquarters

Fremont, CA 94538, US

CTKB Financials

Key Financial Metrics (TTM)

Gross Margin

51.70%

Operating Margin

-21.49%

Net Income Margin

-36.25%

Return on Equity

-20.77%

Return on Capital

-11.05%

Return on Assets

-16.48%

Earnings Yield

-12.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$586.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

129.14M

Volume

0

Avg. Volume

1.40M

Financials (TTM)

Gross Profit

$105.56M

Operating Income

-$43.87M

EBITDA

-$22.15M

Operating Cash Flow

-$7.30M

Capital Expenditure

-$5.40M

Free Cash Flow

-$12.70M

Cash & ST Invst.

$262.23M

Total Debt

$36.33M

Cytek Biosciences Performance Analysis

Cytek Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 164,036,00028.2%
20232023-12-31USD 193,015,00017.7%
20242024-12-31USD 200,453,0003.9%
20252025-12-31USD 201,493,0000.5%
Cytek Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.0%
Q32025-09-3014.7%
Q42025-12-3118.8%
Q12026-03-31-29.0%
Cytek Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.02N/A
20232023-12-31USD -0.09N/A
20242024-12-31USD -0.05-48.7%
20252025-12-31USD -0.521029.9%
Cytek Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3051.1%
Q32025-09-302.5%
Q42025-12-31-692.5%
Q12026-03-3155.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$44.14M

+6.5%

Gross Profit

$21.25M

+5.4%

Gross Margin

48.16%

N/A

Market Cap

$586.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$884.33K

N/A

Employees

663

N/A

Net Income

-$18.87M

-65.5%

EBITDA

-$14.30M

-76.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$262.23M

-1.3%

Total Debt

$36.33M

+128.5%

Accounts Receivable

$56.48M

+2.3%

Inventory

$49.79M

+9.8%

Long Term Debt

$20.46M

+144.6%

Short Term Debt

$15.86M

+110.6%

Return on Assets

-16.48%

N/A

Return on Invested Capital

-11.92%

N/A

Free Cash Flow

-$4.90M

-402.5%

Operating Cash Flow

-$2.74M

-2088.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANGOAngioDynamics, Inc.
$13.82-2.81%
SRDXSurmodics, Inc.
$42.98+0.35%
CBLLCeriBell, Inc.
$16.82-5.98%
KIDSOrthoPediatrics Corp.
$19.26-1.18%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About CTKB

What is the current price of Cytek Biosciences?

Cytek Biosciences is trading at $4.53 per share.

What is the 52-week range for Cytek Biosciences?

Over the past 52 weeks, Cytek Biosciences has traded between $3.20 and $6.18.

How much debt does Cytek Biosciences have?

As of the most recent reporting period, Cytek Biosciences reported total debt of $36.33M.

How much cash does Cytek Biosciences have on hand?

Cytek Biosciences reported $65.67M in cash and cash equivalents in its most recent financial results.

What is Cytek Biosciences’s dividend yield?

Cytek Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services